Clinical Trial Update: A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SHR6390 in combination with famitinib for HR+/HER2- advanced/metastatic breast cancer is underway, with status and results n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Famitinib (Famitinib)
• SHR6390 (SHR6390)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN